THE PROBLEM

Depression is a leading cause of disability and suffering worldwide. 300 million people suffer from depression globally, costing the world economy USD 1 trillion in lost productivity.

Depression costs the Australian economy AUD 6 billion in direct and indirect costs..

1 in 3 patients recovering from their first depression episode is likely to relapse, turning depression into a chronic disease.

Prolonged sympathetic nervous arousal or fight or flight activity in the body is a leading risk factor for depression relapse.

Relapse turns depression into a chronic disease

Philia Labs’ solution for relapse prevention

What it is:

  • User-friendly platform to enable earlier interventions by the clinician
  • Patient-friendly wearable
  • Clinically validated algorithms to quantify stress in real-time
  • Reporting system for clinician

Who it is for:

  • Patients undergoing depression treatment and at risk of relapse
  • Psychiatrist prescribes wearable + data monitoring program

A new standard for measuring sympathetic arousal in the body

  • Using the body’s stress response as gold standard
  • Regulatory-approved wearable sensor
  • Real-time measurement
  • TEAM

    DILPREET
    BUXI

    PhD
    CEO &
    Co-founder

    ALEXANDER SENIOR

    BSc, BEng (Hons)
    Head of Product & Co-founder

    DAVID
    LESTER

    PhD
    Head of Strategy & Medical Affairs

    MELANIE J. WHITE

    BSc (Hons), Wellness coaching NBHWC
    Patient Engagement

    KATI SARAFRAZI

    PhD
    Biomedical Data Scientist

    NICHOLAS MELLOR

    BSc, BEng
    Algorithm Engineer

    MADHURA MAHAMUNKAR

    MSc
    Applications Engineer

    AUDREY
    TAN

    BSc
    IT Engineer

    RITA KOUCHAYAN

    M. Org. Leadership
    User Experience

    Our Advisors

    PAUL FITZGERALD

    MBBS, MPM, PhD
    Strategic Clinical Advisor

    VINAYAK SMITH

    MBBS
    Clinical Strategy

    OUR PARTNERS

    Get in touch with us